1-(1H-Imidazol-1-yl)ethyl tetradecanoate | 562069-47-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-(1H-Imidazol-1-yl)ethyl tetradecanoate
• 英文别名: 1-imidazol-1-ylethyl tetradecanoate
• CAS: 562069-47-0
• 化学式: C₁₉H₃₄N₂O₂
• 分子量: 322.5
• InChiKey: LINNUSCVVYVOLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  23
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Method and composition for preventing pain in sickle cell patients
  申请人：——

  公开号：US20040072796A1

  公开（公告）日：2004-04-15

  A method of preventing pain in a sickle cell patient is disclosed. The method includes orally administering to the patient, an amount of an active agent effective on oral administration to inhibit binding of the patient's sickle erythrocytes to P-selectin on the patient's vascular endothelium. The inhibition may be evidenced in a number of ways. The active agent administration inhibits the adhesion of sickle erythrocytes to vascular endothelium in the patient, thereby preventing patient pain associated with vascular occlusion. Also disclosed are compositions useful in practicing the method.

  本发明公开了一种预防镰状细胞患者疼痛的方法。该方法包括向患者口服一定量的活性剂，口服后可有效抑制患者镰状红细胞与患者血管内皮上的 P-选择素结合。抑制作用可通过多种方式体现。活性剂给药可抑制镰状红细胞与患者血管内皮的粘附，从而防止患者因血管闭塞而产生疼痛。还公开了用于实施本方法的组合物。
• METHOD AND COMPOSITION FOR PREVENTING PAIN IN SICKLE CELL PATIENTS
  申请人：Embury, Stephen H.

  公开号：EP1542704A1

  公开（公告）日：2005-06-22
• HEPARIN COMPOSTIONS AND SELECTIN INHIBITION
  申请人：The Regents of the University of California, Office of Technology Transfer, University of California

  公开号：EP1906974A2

  公开（公告）日：2008-04-09
• Heparin compositions and selectin inhibition
  申请人：Varki Ajit

  公开号：US20070021378A1

  公开（公告）日：2007-01-25

  The disclosure provides in vitro and in vivo methods for identifying Heparins and Heparinoids that modulate the activity of selecting. The disclosure also provides Heparins and Heparinoids that modulate the activity of selecting. The identification and isolation of these heparin formulations has the potential to mediate a wide variety of pathologies mediated by P- and/or L-selectin, including hematogenous metastasis, diseases associated with inflammation (e.g., asthma, arthritis, allergic dermatitis), ischemia-reperfusion injury, or other pathologies such as sickle cell anemia. Selectin inhibition can be achieved at plasma concentrations lower than those that cause excessive anticoagulation or unwanted bleeding in a human subject.
• Heparin Compositions and Selectin Inhibition
  申请人：Varki Ajit

  公开号：US20100081630A1

  公开（公告）日：2010-04-01

  The disclosure provides in vitro and in vivo methods for identifying Heparins and Heparinoids that modulate the activity of selectins. The disclosure also provides Heparins and Heparinoids that modulate the activity of selectins. The identification and isolation of these heparin formulations has the potential to mediate a wide variety of pathologies mediated by P- and/or L-selectin, including hematogenous metastasis, diseases associated with inflammation (e.g., asthma, arthritis, allergic dermatitis), ischemia-reperfusion injury, or other pathologies such as sickle cell anemia. Selectin inhibition can be achieved at plasma concentrations lower than those that cause excessive anticoagulation or unwanted bleeding in a human subject.